Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SOLARAZE

Solaraze is a drug marketed by Fougera Pharms and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SOLARAZE is diclofenac sodium. There are fourty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the diclofenac sodium profile page.

Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and HeadStatus: Completed Condition: Photosensitivity Disorders

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.